Clinical relevance of drug interactions;Interacciones medicamentosas: Aproximación para establecer y evaluar su relevancia clínica

Medicina Clinica

Volumn 129, Issue 1, 2007, Pages 27-35

  Amariles, Pedro ^a,b,c   Giraldo, Newar Andrés ^a,b,d   Faus, María José ^c  

^a Departamento de Farmacia   (Colombia)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c UNIVERSITY OF GRANADA   (Spain)

^d Humax Pharmaceutical   (Colombia)

Author keywords

Bioavailability; Cytochrome P 450; Drug interactions; Pharmacokinetic drug interactions

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; AZITHROMYCIN; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450; DILTIAZEM; ERYTHROMYCIN; FAMOTIDINE; FLUCONAZOLE; FLUOXETINE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NELFINAVIR; NIFEDIPINE; RANITIDINE; RAPAMYCIN; RITONAVIR; SAQUINAVIR; TACROLIMUS; TERBINAFINE; TIPRANAVIR; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL; VORICONAZOLE;

DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PHARMACODYNAMICS; REVIEW;

EID: 34548677317     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13106681     Document Type: Review

References (86)

1. Panel de Consenso. Segundo Consenso de Granada Sobre Problemas Relacionados con Medicamentos. Ars Pharmaceutica. 2002;43:175-84.
2. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (Wash). 2004;44:136-41.
3. Amariles P. Interacciones medicamentosas. En: Amariles P, editor. El medicamento. Compendio básico para su utilización correcta. Medellín: Impresos LTDA; 2002. p. 155-246.
4. U.S. Food and Drug Administration. Managing the risks from medical product use. Part 4: Managing the risks from medical product use. Washington DC: U.S. Department of Health and Human Services, Food and Drug Administration; 1999 [consultado 04/07/2006]. Disponible en: http://www.fda.gov/oc/tfrm/Part4. html
5. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53:4-9.
6. Hughes CE, Gardiner SJ, Begg EJ, Zhang M. Effect of pregnancy on the pharmacokinetics of metformin. Diabet Med. 2006;23:323-6.
7. Daikha-Dahmane F, Levy-Beff E, Jugie M, Lenclen R. Foetal kidney mal-development in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol. 2006;21:729-32.
8. Santos CA, Boullata JI. An approach to evaluating drug-nutrient interactions. Pharmacotherapy. 2005;25:1789-800.
9. Tirona RG, Bailey DG. Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol. 2006;61:677-81.
10. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 2006;78:2131-45.
11. Launay-Vacher V, Izzedine H, Karie S, Hulot JS, Baumelou A, Deray G. Renal tubular drug transporters. Nephron Physiol. 2006;103:97-106.
12. US Food and Drug Administration, 1999. Guidance for industry: in vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. Rockville: Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 1999.
13. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997;44:190-4.
14. De Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet. 2003;42:223-82.
15. Boffito M, Maitland D, Pozniak A. Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies. J Clin Pharmacol. 2006;46:130-9.
16. Fellay J, Marzolini C, Decosterd L, Golay KP, Baumann P, Buclin T, et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol. 2005;60:865-73.
17. Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2001;40:207-26.
18. Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. Br J Clin Pharmacol. 1998;46:111-6.
19. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos. 2001;29:754-60.
20. Tran JQ, Petersen C, Garrett M, Hee B, Kerr BM. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clin Pharmacol Ther. 2002;72:615-26.
21. Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 2005;19:145-52.
22. Hynninen VV, Olkkola KT, Leino K, Lundgren S, Neuvonen PJ, Rane A, et al. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. Antimicrob Agents Chemother. 2006;50:1967-72.
23. Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005;78:520-8.
24. Abu-Gharbieh E, Vasina V, Poluzzi E, De Ponti F. Antibacterial macrolides: a drug class with a complex pharmacological profile. Pharmacological Research. 2004;50:211-2.
25. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant. 2004;4:1514-22.
26. Martínez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Márquez M, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999;65:31-9.
27. Kinzig-Schippers M, Fuhr U, Zaigler M, Dammeyer J, Rusing G, Labedzki A, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther. 1999;65:262-74.
28. Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrera I, Ford N, et al. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther. 2001;69:96-103.
29. Madani S, Barilla D, Cramer J, Wang Y, Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol. 2002;42:1211-8.
30. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000;40:58-66.
31. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol. 2002;22:169-73.
32. Labbe L, O'Hara G, Lefebvre M, Lessard E, Gilbert M, Adedoyin A, et al. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmacol Ther. 2000;67:44-57.
33. Werner D, Wuttke H, Fromm MF, Schaefer S, Eschenhagen T, Brune K, et al. Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol. 2004;94:1319-21.
34. Lessard E, Yessine MA, Hamelin BA, Gauvin C, Labbe L, O'Hara G, et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol. 2001;21:175-84.
35. Marraffa JM, Lang L, Ong G, Lehmann DF. Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene. Clin Pharmacol Ther. 2006;79:282-6.
36. Tornio A, Neuvonen PJ, Backman JT. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol. 2006; 62:645-51.
37. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005;77:404-14.
38. Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, Frye RF. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br J Clin Pharmacol. 2005;59:70-9.
39. Laine K, Tybring G, Bertilsson L. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther. 2000;68:151-9.
40. Chien JY, Peter RM, Nolan CM, Wartell C, Slattery JT, Nelson SD, et al. Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Clin Pharmacol Ther. 1997;61:24-34.
41. Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther. 2000;67:275-82.
42. Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol. 2002;57:799-804.
43. Wen X, Wang JS, Kivisto KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52:547-53.
44. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61:246-55.
45. Kuypers DR, Verleden G, Naesens M, Vanrenterghem Y. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther. 2005;78:81-8.
46. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162:985-9.
47. Nallani SC, Glauser TA, Hariparsad N, Setchell K, Buckley DJ, Buckley AR, et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003;44:1521-8.
48. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005;71:402-8.
49. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol. 2006;62:225-33.
50. Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ. 2004;329:27-30.
51. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol. 2006;62:29-36.
52. Choudhuri S, Valerio LG Jr. Usefulness of studies on the molecular mechanism of action of herbals/botanicals: the case of St. John's wort. J Biochem Mol Toxicol. 2005;19:1-11.
53. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290:1500-4.
54. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-21.
55. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther. 2006;109:137-61.
56. Balimane PV, Chong S. Combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay. Int J Pharm. 2005;301:80-8.
57. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest. 2003;33 Suppl 2:6-9.
58. Fugh-Berman A, Myers A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp Biol Med (Maywood). 2004;229:698-704.
59. Andersen V, Pedersen N, Larsen NE, Sonne J, Larsen S. Intestinal first pass metabolism of midazolam in liver cirrhosis - effect of grapefruit juice. Br J Clin Pharmacol. 2002;54:120-4.
60. Huang SM, Hall SD, Watkins P, Love LA, Serabjit-Singh C, Betz JM, et al. Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther. 2004;75:1-12.
61. Dahan A, Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent and relevance. Eur J Clin Nutr. 2004;58:1-9.
62. Kim H, Yoon Y-J, Shon J-H, Cha I-J, Shin J-G, Liu K-H. Inhibitory effects of fruit juices on CYP3A activity. Drug Metab Dispos. 2006;34:521-3.
63. Goosen TC, Cillie D, Bailey DG, Yu C, He K, Hollenberg PF, et al. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin Pharmacol Ther. 2004;76:607-17.
64. Kakar SM, Paine MF, Stewart PW, Watkins PB. 6′7′- dihydroxybergamottin contributes to the grapefruit juice effect. Clin Pharmacol Ther. 2004;75:569-79.
65. Girennavar B, Poulose SM, Jayaprakasha GK, Bhat NG, Patil BS. Furocoumarins from grapefruit juice and their effect on human CYP 3A4 and CYP 1B1 isoenzymes. Bioorg Med Chem. 2006;14:2606-12.
66. Grenier J, Fradette C, Morelli G, Merritt GJ, Vranderick M, Ducharme MP. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther. 2006;79:255-66.
67. Paine MF, Widmer WW, Hart HL. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr. 2006;83:1097-105.
68. Lin HL, Kent UM, Hollenberg PF. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther. 2005;313:154-64.
69. Egashira K, Ohtani H, Itoh S, Koyabu N, Tsujimoto M, Murakami H, et al. Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab Dispos. 2004;32:828-33.
70. Greenblatt DJ, Von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther. 2003;74:121-9.
71. Culm-Merdek KE, Von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006;79:243-54.
72. Ofer M, Wolffram S, Koggel A, Spahn-Langguth H, Langguth P. Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT? Eur J Pharm Sci. 2005;25:263-71.
73. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005;33:518-23.
74. Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther. 2004;75:184-90.
75. Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol. 2005;61:337-40.
76. Lu WJ, Huang JD, Lai ML. The Effects of Ergoloid mesylates and Ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol. 2006;46:628-34.
77. Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y, et al. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci. 2006;78:2852-9.
78. Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, et al. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther. 2005;77:291-301.
79. Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther. 2005;77:170-7.
80. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003;73:192-8.
81. Tomlinson B, Chow MSS. Stereoselective interaction of manidipine and grapefruit juice: a new twist on an old tale. Br J Clin Pharmacol. 2006;61:529-32.
82. Ohnishi A, Ohtani H, Sawada Y. Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists. Br J Clin Pharmacol. 2006;62:196-9.
83. Kharasch ED, Walker A, Hoffer C, Sheffels P. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. J Clin Pharmacol. 2005;45:79-88.
84. Van Harten J, Van Brummelen P, Lodewijks MT, Danhof M, Breimer DD. Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. Clin Pharmacol Ther. 1988;43:332-41.
85. Strain JJ, Chiu NM, Sultana K, Karim A, Caliendo G, Mustafa S. Psychotropic drug versus psychotropic drug-update. Gen Hosp Psychiatric. 2004;26:87-105.
86. Peng CC, Glassman PA, Trilli LE, Hayes-Hunter J, Good CB. Incidence and severity of potential drug-dietary supplement interactions in primary care patients. Arch Intern Med. 2004;164:630-6.